RxDoctor Payments Data

Bradley Borsboom, APRN

Psychiatric/Mental Health · Kingwood, TXNPI 1740717180

Payments from drug & device makers

$1,984in general payments, 2019–2025

Across 91 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$580
  • Alkermes, Inc.$217
  • Takeda Pharmaceuticals U.S.A., Inc.$196
  • Otsuka America Pharmaceutical, Inc.$147
  • Axsome Therapeutics, Inc.$137
  • Sunovion Pharmaceuticals Inc.$104
  • plus $603 from 13 others

What the payments were for

  • Food & beverage$1,976100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,984 in reported general payments places this provider in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$17,429
Medicare patients
54
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$108,668
RexultiBrexpiprazole29$58,025
VraylarCariprazine Hcl20$28,917
ValiumDiazepam13$18,893
TrintellixVortioxetine Hydrobromide26$12,785
SuboxoneBuprenorphine Hcl/Naloxone Hcl15$12,000
QuviviqDaridorexant Hcl13$6,470
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$5,954
Ziprasidone Hcl54$3,874
Aripiprazole60$2,181
Clozapine20$2,135
Oxcarbazepine46$2,028
Carbamazepine ErCarbamazepine16$1,441
Quetiapine Fumarate111$1,366
Alprazolam150$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$54$108,66813 claims
Otsuka America Pharmaceutical, Inc.Rexulti$147$58,02529 claims
AbbVieVraylar$580$28,91720 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$196$12,78526 claims
Idorsia Pharmaceuticals US IncQuviviq$32$6,47013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Kingwood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →